Compounds having formula (I) (IX), and enantiomers, and diastereomers, stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein: (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX).
[EN] AMINOIMIDAZOPYRIDAZINES AS KINASE INHIBITORS<br/>[FR] AMINOIMIDAZOPYRIDINES UTILISÉES EN TANT QU'INHIBITEURS DE KINASE
申请人:BRISTOL MYERS SQUIBB CO
公开号:WO2019089442A8
公开(公告)日:2019-06-27
AMINOTRIAZOLOPYRIDINES AS KINASE INHIBITORS
申请人:Bristol-Myers Squibb Company
公开号:EP3580220B1
公开(公告)日:2021-11-17
AMINOIMIDAZOPYRIDAZINES AS KINASE INHIBITORS
申请人:Bristol-Myers Squibb Company
公开号:EP3704118A1
公开(公告)日:2020-09-09
[EN] AMINOTRIAZOLOPYRIDINES AS KINASE INHIBITORS<br/>[FR] AMINOTRIAZOLOPYRIDINES UTILISÉES EN TANT QU'INHIBITEURS DE KINASE
申请人:BRISTOL MYERS SQUIBB CO
公开号:WO2018148626A1
公开(公告)日:2018-08-16
Compounds having formula (I) (IX), and enantiomers, and diastereomers, stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein: (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX).